Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion type Assertion NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_head.
- NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion description "[9p24 gains were detected in 6/17 (35%) primary mediastinal B-cell lymphomas (PMBCLs), 25/77 (33%) Hodgkin's lymphomas (HLs), 3/16 (19%) angioimmunoblastic T-cell lymphomas (AILTs) and 1/5 ALK1(+) anaplastic large cell lymphomas (ALCLs); breaks were observed only in three cases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_provenance.
- NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion evidence source_evidence_literature NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_provenance.
- NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion SIO_000772 19136931 NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_provenance.
- NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion wasDerivedFrom befree-20140225 NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_provenance.
- NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_assertion wasGeneratedBy ECO_0000203 NP681744.RAw4yyoTEJS6y_PPuuEpVC881_eJrMc9JlLDa_US52D3g130_provenance.